The U.S. Drug Enforcement Administration is asking a federal appeals court to throw out a lawsuit aimed at clearing a path to the therapeutic use of psilocybin, the main psychoactive compound in psychedelic mushrooms—arguing that allowing limited medical access could boost the illegal drug trade.
A California Assembly committee on Tuesday approved a Senate-passed bill to legalize possession of psychedelics, clearing its first major hurdle in the chamber.
An Oregon review panel established under the state’s voter-approved therapeutic psilocybin legalization initiative has released a report stating that the psychedelic holds significant medical value for a number of mental health conditions.
The Mental Health Crisis has been ignored for decades. Covid-19 has made this mental health catastrophe much worse -- and people are now starting to notice.
MindMed is preparing to commence a Phase I clinical trial on the safety/tolerance of intravenous DMT.
Cybin's new financing is priced at CAD$3.40. The Company intends to issue 8.8 million new units for total proceeds of CAD$30 million.
Cybin Inc is seeking to raise capital with an overnight offering of common shares. Pricing and size of the offering to be determined.
We explain why addiction therapy likely offers the greatest long-term commercialization potential within the psychedelic drug industry.